CTLA4 and neoplasm: CTLA-4 inhibitors lacking the Fc structural domain do not induce colitis in colitis-prone mice when receiving conventional anti-CTLA-4 antibodies. Notably, anti-CTLA-4 VHHs can resist tumor responses without inducing gut irAEs in mice (64).